1. Introduction {#sec1}
===============

Herbal medicine was gradually being used as an alternative and/or complementary treatment for serious diseases \[[@B1]\].*Corydalis decumbens* (Thunb.) Pers, a herbal medicine, was named "Xiatianwu" in China. Cultivation base of "Xiatianwu" was officially approved by Good Agriculture Practices (GAP), in China since 1980.*Corydalis decumbens*, also a Traditional Chinese Medicine (TCM), has been widely used for the treatment of hypertension, hemiplegia or cerebral embolism hemiplegia, paralytic stroke, rheumatic arthritis, and sciatica \[[@B2]\]. Earlier clinical and/or preclinical studies also have demonstrated that*Corydalis decumbens* (tablet/injection) has exerted the benefit effect on hypertension \[[@B3]\], rheumatoid arthritis \[[@B4]\], sciatica \[[@B5]\], trigeminal neuralgia \[[@B6]\], inhibiting platelet aggregation \[[@B7]\], and memory \[[@B8]\]. Thus, besides clinical doctor\'s recommendations, many patients take western medication in combination with*Corydalis decumbens* or other herbal medicine which they think is safe and often not inform self-medication to their primary physician \[[@B9]--[@B12]\]. However, there is a potential for herb--drug interactions between herbal medicine and western medicine \[[@B7]\]. The herb--drug interactions are implicated in pharmacokinetic and pharmacodynamic effects and may lead to serious adverse events or even death \[[@B13]\]. In order to avoid clinically insufficient benefits and/or unacceptable risks, it is important to discover and identify harmful combination interactions.

Cytochrome P450 (CYP), a superfamily of enzymes, is the main phase 1 enzyme system for the metabolism of various exogenous, endogenous components, and herbal substance \[[@B14], [@B15]\]. Among many CYP enzymes, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are the major contributors to metabolizing a vast majority of widely known drugs \[[@B16], [@B17]\]. Inhibition or induction of specific enzymes has been considered as the mainly modulated factor for herb--drug interactions (HDIs), which can appear when herb and western medication are combined administration \[[@B18]--[@B20]\]. Therefore, it is essential to understand the inhibitive and inductive effects of CYP enzymes, in order to predict the potential HDI.

The present work was to evaluate the effects of*Corydalis decumbens* on the activities of CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The cocktail approach was effectively used to monitor the activities of CYP enzymes and recognized as one of the specific analytical tools to study herb--drug interactions \[[@B21], [@B22]\]. Five probe drugs (CYP1A2 for phenacetin \[[@B23]\], CYP2C9 for tolbutamide \[[@B24]\], CYP2C19 for omeprazole \[[@B25]\], CYP2D6 for metoprolol \[[@B26]\], and CYP3A4 for midazolam \[[@B27]\]) were analysed in rat plasma with a specific and sensitive UHPLC--MS/MS method. Several studies have demonstrated that rat CYPs (1A2, 2C6, 2D1, 2D2, and 3A1/2) are homologous to human CYPs (1A2, 2C9, 2C19, 2D6, and 3A4), respectively \[[@B17], [@B19], [@B28]\]. Therefore, the results from rats could be extrapolated to human in clinical use \[[@B17], [@B19]\]. Five CYP enzymes activities were analysed by comparing pharmacokinetics of corresponding probe drugs between XTW and control treatment groups. We hope that our results will be helpful for avoiding the insufficient benefits and serious adverse effects of herb--drug interactions between*Corydalis decumbens* and western medicine.

2. Materials and Methods {#sec2}
========================

2.1. Chemicals {#sec2.1}
--------------

Phenacetin, omeprazole, metoprolol, tolbutamide, midazolam (purity \> 98%), and carbamazepine (internal standard, IS) were provided by Sigma--Aldrich Co. (St. Louis, MO, USA).*Corydalis decumbens* injection was obtained from Jiang Xi Herbi-sky Co., Ltd. (JiangXi, China). A Milli--Q system (Millipore Co., USA) was used to produce ultrapure water. Other chemical reagents (analytical grade) used were from standard chemical suppliers.

2.2. Animals {#sec2.2}
------------

Male Sprague--Dawley rats (n=12, weighing 220±20 g) were obtained from Laboratory Animal Research Center of Wenzhou Medical University (Wenzhou, China). The rats were kept in house cages with a temperature 22±2°C, humidity 50±5%, and light--dark (12 h/12 h) cycle. They were maintained in house cages for at least one week prior to study pharmacokinetics experimentation and fed with food and drinking water freely. All experimental procedures in present study were approved strictly by the Animal Care and Use Committee of Wenzhou Medical University.

2.3. Apparatus and UHPLC--MS/MS Conditions {#sec2.3}
------------------------------------------

To analyse the mixed compounds, the UHPLC--MS/MS was employed. Chromatographic analysis was executed by an Agilent 1290 UHPLC system. The mass spectrometry was Agilent 6420 Series Triple Quadrupole Tandem Mass Spectrometer (Santa Clara, CA, USA) equipped with an electrospray ionization source in the positive-ion mode. MassHunter Agilent Software (version B.07.00) was used for setting instrument condition parameters and analysing data.

Separation of five probes and the IS was based on the conditions described previously \[[@B17]\]. They were separated using a 2.1 × 50 mm, 1.8 *μ*m particle, Agilent ZORBAX Eclipse Plus C18 Rapid Resolution HD column at a constant temperature of 30°C. Formic acid--water, 1/1000, v/v (mobile phase A), and acetonitrile (mobile phase B) were prepared as initial mobile phases, which were ultrasonically degassed before use. A gradient elution program was as follows: 0--0.3 min (30% B); 0.3--1.3 min (30%--50% B); 1.3--1.8 min (50%--95%B); 1.8--2.8 min (95% B). The posttime was 1.0 min for equilibration of the column, and the total run time was 3.8 min. The flow rate was 0.4 mL·min^−1^.

Nitrogen was considered as desolvation gas (10 L/h). The nebuliser pressure and desolvation temperature of drying gas (both nitrogen) flow were adjusted to 45 psi and 350°C, respectively. The capillary voltage was set to 4 KV. The quantitative analysis of target ions was performed in multiple reaction monitoring (MRM) mode with m/z 180.1→109.9 for phenacetin, m/z 346.1→135.9 for omeprazole, m/z 268.2→115.9 for metoprolol, m/z 271.1→91.0 for tolbutamide, m/z 326.1→ 290.8 for midazolam, and m/z 237.1→194.0 for the IS.

2.4. Pharmacokinetics {#sec2.4}
---------------------

The study was conducted in accordance with the BCPT policy for experimental and clinical studies \[[@B29]\]. The above 12 male Sprague--Dawley rats were randomly divided into 2 groups:*Corydalis decumbens* treatment group (XTW group) (n = 6) and control group (n = 6).*Corydalis decumbens* and saline (5 mL/kg via gavage, i.g.) were administrated for 7 successive days. A probe cocktail solution was prepared by phenacetin (10 mg/kg), omeprazole (10 mg/kg), metoprolol (10 mg/kg), tolbutamide (1 mg/kg), and midazolam (10 mg/kg) diluted with saline. The probe cocktail solution (4 mL/kg via i.g.) was given 24 h after the last dose of saline or*Corydalis decumbens*.

Tail vein blood samples (0.25-0.3 mL) were collected into 1.5 mL heparinized polyethylene tubes at 0.17, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 h, after probe drugs administration. The blood samples were centrifuged at 10,000 g for 10 min and plasma layers were dispatched aliquots of 100 *μ*L and frozen at --80°C until analysis.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Drug and statistics (DAS) software (version 3.0) was used to calculate the pharmacokinetic parameters. The results were expressed as a mean ± standard deviation (SD). All analyses for the main pharmacokinetic parameters of the 2 groups were performed with the IBM SPSS software system statistics (version 23.0) by use of Student\'s t-test. Statistical significance was accepted if a value of p \< 0.05.

3. Results {#sec3}
==========

3.1. Method Validation {#sec3.1}
----------------------

The regression type of each analyte in a certain range, correlation coefficient, and calibrations were shown in [Table 1](#tab1){ref-type="table"}. The calibration curves showed good linearity over the selected concentration in all analyte samples with a correlation coefficient (R^2^) \> 0.990. The lower limit of quantification(LLOQ) was 5.43 ng/mL for phenacetin, 3.43 ng/mL for tolbutamide, 5.65 ng/mL for omeprazole, 5.33 ng/mL for metoprolol, and 4.46 ng/mL for midazolam.

As shown in [Figure 1](#fig1){ref-type="fig"}, the retention times of relevant analytes (phenacetin, tolbutamide, omeprazole, metoprolol, and midazolam) and IS determined by a UHPLC-MS/MS method in rat plasma were 1.035, 2.649, 0.529, 0.448, 0.715, 1.827 min, respectively. Meanwhile, there were no interferences of endogenous interfering peaks near the relative retention time for analytes in EIC chromatograms. The dates of precision, accuracy, recovery, and matrix effect of five probes were summarized in [Table 2](#tab2){ref-type="table"}. The intraday and interday precisions ranged from 2.25% to 10.85% and 2.90% to 9.74%, respectively. The intraday and interday accuracies changed from 95.56% to 106.24% and 97.26% to 103.97%, respectively. The extraction recoveries for phenacetin, tolbutamide, omeprazole, metoprolol, and midazolam were larger than 83.5%. The matrix effects for all analytes ranged from 95.26% to 102.59%. Abovementioned results were collected in [Table 2](#tab2){ref-type="table"}.

3.2. Effect of*Corydalis decumbens* on the CYP1A2 Activity {#sec3.2}
----------------------------------------------------------

Pharmacokinetic profiles of phenacetin in two different treatment groups were used to depict CYP1A2 activity. As shown in [Figure 2(a)](#fig2){ref-type="fig"} and Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b), XTW group significantly prolonged T~1/2~ and increased MRT~(0--t)~ and MRT~(0--*∞*)~ (P\<0.05, P\<0.01), when compared with control group. Other pharmacokinetic parameters (C~max~, AUC and CLz/F) of phenacetin in the XTW group showed no obvious differences, comparing with control group (P\>0.05). These indicated that*Corydalis decumbens* might inhibit the activity of CYP1A2.

3.3. Effect of*Corydalis decumbens* on the CYP2C9 Activity {#sec3.3}
----------------------------------------------------------

Tolbutamide\'s pharmacokinetic parameters in two different groups were expressed in [Figure 2(b)](#fig2){ref-type="fig"} and Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b). There were no obvious differences in the pharmacokinetic parameters in XTW and control groups, which indicated that*Corydalis decumbens* did not influence the activity of CYP2C9 in blood samples.

3.4. Effect of*Corydalis decumbens* on the CYP2C19 Activity {#sec3.4}
-----------------------------------------------------------

The activity of CYP2C19 was evaluated by measuring the omeprazole\'s pharmacokinetic parameters in different groups ([Figure 2(c)](#fig2){ref-type="fig"}, Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b)). T~1/2~, T~max~, MRT~(0--t)~, MRT~(0--*∞*)~, AUC~(0--t)~, and AUC~(0--*∞*)~ values of omeprazole in rats treated by*Corydalis decumbens* decreased significantly (P\<0.05, P\<0.01). The value of CLz/F for omeprazole was increased significantly with*Corydalis decumbens* treatment, comparing with control group (P\<0.05). These date demonstrated that metabolism of omeprazole was obviously accelerated by*Corydalis decumbens* treatment, and it had potential to induct the CYP2C19 activity in blood samples.

3.5. Effect of*Corydalis decumbens* on the CYP2D6 Activity {#sec3.5}
----------------------------------------------------------

The activity of CYP2D6 was assessed by comparing the metoprolol\'s pharmacokinetic parameters between XTW and control groups. As shown in [Figure 2(d)](#fig2){ref-type="fig"} and Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b), the effect of*Corydalis decumbens* on the all pharmacokinetic parameters of metoprolol was no significant change, comparing with control group. Thus, metoprolol\'s pharmacokinetic behaviors demonstrated that the CYP2D6 activity might not be inhibited or inducted by*Corydalis decumbens*.

3.6. Effect of*Corydalis decumbens* on the Activity of CYP3A4 {#sec3.6}
-------------------------------------------------------------

As shown in [Figure 2(e)](#fig2){ref-type="fig"} and Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b), pharmacokinetic behaviors of midazolam were significant differences in XTW and control treatment groups. The value of T~1/2~ and C~max~ for midazolam was increased significantly with*Corydalis decumbens* treatment (P\<0.05, P\<0.01), and the value of CLz/F was decreased obviously (P\<0.05). It indicated that*Corydalis decumbens* might prolong the elimination and increase midazolam absorbed into blood. Meanwhile, other pharmacokinetic parameters (MRT~(0--t)~, MRT~(0--*∞*)~, AUC~(0--t)~, and AUC~(0--*∞*)~ were increased significantly (P\<0.01) with*Corydalis decumbens* treatment. These date showed that the activity of CYP3A4 might be inhibited by*Corydalis decumbens*.

4. Discussion {#sec4}
=============

In the present study, the potential effects of*Corydalis decumbens* on the activities of CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) were detected by a novel UHPLC-MS/MS method. The method was validated for the determination of novel "cocktail" in linearity, accuracy, precision, selectivity, recovery, matrix effect, and stability and successfully applied in the pharmacokinetic study. Our results indicated that the activities of CYP1A2 and CYP3A4 might be inhibited by*Corydalis decumbens*. And, the activity of CYP2C19 was induced by*Corydalis decumbens*. However, there were no significant differences in pharmacokinetics dates of tolbutamide and metoprolol between two different groups, which demonstrated that the activities of CYP2C9 and CYP2D6 were not obviously influenced by*Corydalis decumbens*.

Recently, herbal medicine is an increasingly common form of alternative and/or complementary therapy in several countries (e.g., China, United States, Japan, Korea, Sweden, France, Germany, and Australia) \[[@B1]\]. Often herbal products are regulated as dietary supplements and patients typically think it is safer than pharmaceutical drugs \[[@B30]--[@B32]\]. But, several studies specifically defined that the concurrent use of herbal medicines and prescription drugs may trigger the potentiality of herb--drug interactions \[[@B33], [@B34]\]. These interactions may cause the inhibition or induction of specific CYP enzymes and elicit pharmacokinetic and pharmacodynamic mechanisms which may result serious clinical consequences \[[@B18]\]. Thus, it is important to update and improve pharmacist\'s and physician\'s knowledge of HDI to properly counsel and avoid improper concurrent use of herbal medicine and prescription drugs. Chinese Pharmacopoeia recorded that*Corydalis decumbens* plays an important role in terms of hypertension, arrhythmias rheumatoid arthritis, sciatica, stroke, hemiplegia, paraplegia, and vascular embolism \[[@B2]\]. However, there are limited literature and data about HDI in*Corydalis decumbens*. It is important to evaluate whether concurrent administration of herbs may interfere with the effect of drugs.

In the treatment of hypertension,*Corydalis decumbens* could reduce blood pressure by relaxing vascular smooth muscle and reducing peripheral resistance \[[@B3]\]. Propranolol, an antihypertensive medication of the beta blocker class, is mainly metabolized by CYP1A2 and CYP2D6 \[[@B35]\]. Nifedipine, a calcium channel blocker, is mainly metabolized by CYP3A4 \[[@B36]\]. In the present study, the activities of CYP1A2 and CYP3A4 might be inhibited by*Corydalis decumbens*. Thus, the concomitant use of*Corydalis decumbens* can interfere with the pharmacokinetics or pharmacodynamics of propranolol/nifedipine. As a result, the dosage of these drugs may be decreased or the dosing interval be increased.

Rheumatoid arthritis is a systemic immune disease characterized by noninfectious inflammation of the joints and tissues surrounding the joints \[[@B37]\]. Several clinical studies indicated that*Corydalis decumbens* tablets have a benefit effect on alleviating the clinical symptoms of rheumatoid arthritis, with little side effects \[[@B3], [@B38]\]. Diclofenac, a nonsteroidal anti-inflammatory drug, is commonly metabolized by CYP2C9 \[[@B7]\]. The present results showed that the activity of CYP2C9 was not obviously influenced by*Corydalis decumbens*. There was no interaction with the concurrent administration of*Corydalis decumbens* and diclofenac. When a patient requires a concomitant drug to treat rheumatoid arthritis, the therapy may produce synergistic effects and should be favored.

Furthermore,*Corydalis decumbens* were usually used as a complementary medicine for sciatica due to its pharmacological effects of Tongluo analgesics \[[@B2]\]. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID), which relieves pain, fever, swelling, and stiffness. Naproxen is also metabolized by CYP2C9 \[[@B39], [@B40]\]. And, the concurrent use of*Corydalis decumbens* and naproxen is recommended.

Last but not least, cerebrovascular disease is defined as a general term for a group of diseases, which includes stroke, hemiplegia, paraplegia, and vascular embolism, caused by various acute and chronic cerebrovascular diseases. Anticoagulant drugs and antiplatelet agent play an indispensable role in treatment of these diseases, because platelet activation, adhesion, and aggregation are one of the initiating factors of intravascular thrombosis. Warfarin, a vitamin K-antagonist drug, is mainly metabolized by cytochrome P450 enzymes CYP2C9 and CYP1A2 \[[@B41]--[@B43]\]. Our results indicated that the activity of CYP2C9 was not obviously influenced by*Corydalis decumbens*, but CYP1A2 was inhibited. The herb--drug interaction could prolong the elimination and increase warfarin absorbed into blood, which may increase bleeding events. Meanwhile, warfarin has a narrow therapeutic index, especially when combined with potentially interacting drugs. Thus, it is a necessary reminder that the dosage of warfarin can reduce and the dosing interval can increase, when the patients receive long-term concurrent use of*Corydalis decumbens* and warfarin. Clopidogrel is an effective antiplatelet agent useful for the treatment of ischemic cerebrovascular disease by blocking ADP receptors on the platelet membrane \[[@B44]\]. Clopidogrel is metabolized by cytochrome P450 enzymes CYP2C19 \[[@B45]\]. The present study also found that the activities of CYP2C19 were inducted by*Corydalis decumbens*. The clearance rate for clopidogrel may increase significantly with*Corydalis decumbens* treatment. The herb-drug interaction may produce quick therapeutic effect and faster loss of efficacy. When a patient needs a coprescription, it is properly counseled that the dosage of clopidogrel may be increased or the dosing interval may be decreased.

5. Conclusions {#sec5}
==============

The cocktail approach was effectively used as a potential screening tool for effects in vivo HDI. Five probe drugs phenacetin, tolbutamide, omeprazole, metoprolol, and midazolam were selected as specific substrates for rat CYP1A2, CYP2C6, CYP2D1, CYP2D2, and CYP3A1/2, respectively. Also, these probe drugs more often relate to human CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, even though they are given to rats. Thus, the effects of*Corydalis decumbens* determined in rat are also useful for predicting clinical HDIs. Our results indicated that*Corydalis decumbens* could induce the CYP2C19 activity and inhibit the activities of CYP1A2 and CYP3A4. During the concurrent use of*Corydalis decumbens* with western medications which were extensively metabolized by CYP1A2, CYP3A4, and CYP2C19 in human, the herb--drug interaction should require more attention by careful monitoring and appropriate drug dosing adjustments to avoid some unacceptable risks and reduce drug accumulation or ineffective treatment.
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![MRM chromatograms of (a) blank plasma samples, (b) blank plasma samples spiked with the probe drugs, and (c) plasma sample obtained from rat after administration of five cocktail probe drugs.](BMRI2019-9614781.001){#fig1}

![Plasma concentration-time curves of probe drug (phenacetin, tolbutamide, omeprazole, metoprolol, and midazolam). Control Group: the metabolism of the probe drugs in vivo. XTW Group: the metabolism of the probe drugs in vivo after rats received intraperitoneal injection of*Corydalis decumbens*.](BMRI2019-9614781.002){#fig2}

###### 

The calibration curve of phenacetin, metoprolol, midazolam, omeprazole, and tolbutamide in plasma (n=6).

  Analytes      Calibration curves        R^2^          linear range (ng·mL)
  ------------- ------------------------- ------------- ----------------------
  Phenacetin    Y=0.502240*∗*X+0.010662   R^2^=0.9984   2.5-1000ng/ml
  Metoprolol    Y=0.301110*∗*X+0.063879   R^2^=0.9903   2.5-1000ng/ml
  Midazolam     Y=0.219790*∗*X+0.011036   R^2^=0.9965   0.5-200ng/ml
  Omeprazole    Y=0.556111*∗*X+0.030624   R^2^=0.9970   1-1000ng/ml
  Tolbutamide   Y=0.536867*∗*X+0.081507   R^2^=0.9952   20-8000ng/ml

###### 

Precision, accuracy, extraction recovery, and matrix effect of five probes in rat plasma (n=6).

  -----------------------------------------------------------------------------------------------------------------
  Analytes      Concentration added (ng/mL)   Intra-day   Inter-day   Recovery\   Matrix effect\            
                                                                      (%)         (%)                       
  ------------- ----------------------------- ----------- ----------- ----------- ---------------- -------- -------
  Phenacetin    5                             4.93        2.10        4.90        -0.19            83.50    98.41

  100           7.02                          1.69        8.02        2.78        84.71            97.97    

  500           2.42                          -1.39       5.06        -0.93       87.35            102.59   

  Metoprolol    5                             10.85       -0.88       9.74        -0.39            88.98    95.26

  100           8.27                          -3.41       9.16        -2.74       90.76            97.67    

  500           4.70                          1.86        5.90        0.42        87.24            97.27    

  Midazolam     2.5                           8.01        4.40        8.82        0.68             85.62    95.46

  25            8.60                          -0.48       9.22        -2.21       84.02            96.47    

  100           5.65                          0.77        7.56        -0.28       87.48            97.82    

  Omeprazole    5                             5.69        -0.58       6.91        1.72             85.93    98.78

  50            6.45                          4.28        5.15        -2.18       88.93            95.91    

  500           2.25                          6.24        2.90        1.66        86.95            100.34   

  Tolbutamide   100                           2.41        -4.44       8.12        3.97             85.82    98.94

  500           4.17                          1.87        4.66        -0.73       87.43            95.97    

  5000          3.28                          0.41        4.23        -1.19       86.85            99.18    
  -----------------------------------------------------------------------------------------------------------------

###### 

\(a\) Main pharmacokinetic parameters of six in rats (n=6, mean±SD)

  Probe drugs   Parameters   T~1/2~z, h        CLz/F, L/h/kg        C~max~, ng/ml       T~max~,h
  ------------- ------------ ----------------- -------------------- ------------------- -----------------
  Phenacetin    Control      1.364±0.189       12.167±7.187         468.492±174.355     0.473±0.304
                XTW          2.005±0.084*∗∗*   6.489±3.258          715.237±216.924     0.528±0.266
  Metoprolol    Control      2.175±0.350       3.256±1.240          595.115±176.562     3.000±0.894
                XTW          2.137±0.109       3.353±0.672          602.857±164.967     2.583±1.201
  Midazolam     Control      5.426±0.323       31.808±13.079        57.127±22.704       0.723±0.429
                XTW          6.941±0.770*∗∗*   13.913±4.180*∗*      126.572±55.454*∗*   1.167±0.683
  Omeprazole    Control      2.137±0.109       3.353±0.672          602.857±164.967     2.583±1.200
                XTW          1.435±0.222*∗∗*   160.865±125.736*∗*   53.273±28.328*∗∗*   0.335±0.181*∗∗*
  Tolbutamide   Control      7.928±0.501       0.123±0.024          5753.637±1135.602   3.167±0.753
                XTW          8.196±0.400       0.122±0.016          5327.587±586.093    3.667±0.516

*∗*: significantly different from control, p\<0.05. *∗∗*: significantly different from control, p\<0.01.

###### 

\(b\) Main pharmacokinetic parameters of six in rats (n=6, mean±SD)

  Probe drugs   Parameters   MRT~(0--t)~,h     MRT~(0--*∞*)~,h   AUC~(0--t)~, ng/ml·h   AUC~(0--*∞*)~, ng/ml·h
  ------------- ------------ ----------------- ----------------- ---------------------- ------------------------
  Phenacetin    Control      1.881±0.364       1.934±0.336       1158.538±790.101       1162.355±789.191
                XTW          2.460±0.294*∗*    2.630±0.336*∗∗*   1778.848±652.752       1802.074±657.140
  Metoprolol    Control      4.191±0.387       4.629±0.449       3266.639±1033.756      3399.903±1078.993
                XTW          4.003±0.460       4.372±0.524       2995.480±681.621       3098.636±703.838
  Midazolam     Control      6.114±0.409       7.178±0.583       354.710±170.609        371.116±182.508
                XTW          7.236±0.701*∗∗*   9.330±1.093*∗∗*   717.013±231.178*∗*     780.230±260.146*∗*
  Omeprazole    Control      4.004±0.460       4.372±0.524       2995.480±681.621       3098.636±703.838
                XTW          1.747±0.160*∗∗*   1.941±0.176*∗∗*   88.440±45.975*∗∗*      90.921±47.286*∗∗*
  Tolbutamide   Control      11.563±0.526      12.339±0.505      82485.815±16562.483    83822.392±16723.482
                XTW          11.897±0.709      12.742±0.850      81505.311±10227.159    82972.008±10446.975

*∗*: significantly different from control, p\<0.05. *∗∗*: significantly different from control, p\<0.01.
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